hGH Fragment 176-191
Six exact PubMed names returned no clinical trial for native hGH 176-191 (checked 24 Aug 2026). Five exact ClinicalTrials.gov searches also found none. A 1978 rat study found a short blood-sugar rise and a longer insulin rise. AOD-9604 human results belong to a different molecule.
What is hGH Fragment 176-191?
NLM MeSH lists three names (source; checked 24 Aug 2026):
somatotropin (176-191) · hGH (176-191)
The same record gives CAS 66004-57-7.
The fragment is the last 16 amino acids in human GH. Its NLM chemical name starts with phenylalanine and leucine.
GSRS returned no exact match for five names (checked 24 Aug 2026). NLM still provides a CAS for the fragment.
How is this different from AOD-9604?
| Compound | Identity | Human evidence |
|---|---|---|
| hGH Fragment 176-191 | Native hGH residues 176-191; NLM CAS 66004-57-7 | No clinical trial found under six exact PubMed names |
| AOD-9604 | hGH residues 177-191 plus an N-terminal tyrosine; PMID 25208511 | Separate human programme; not transferred here |
Both peptides have 16 amino acids, but start with a different one. The AOD-9604 paper names tyrosine. The NLM name for native 176-191 starts with phenylalanine.
What human evidence is available?
PubMed searched six exact names (checked 24 Aug 2026):
hGH Fragment 176-191 · HGH Frag 176-191 · Frag 176-191 · hGH 176-191 · growth hormone fragment 176-191 · somatotropin (176-191)
Each search found no clinical trial.
The 2022 paper used human MCF-7 cells in a lab. It did not give the fragment to people. No human adverse-event table was found.
What did the 1978 rat study find?
PMID 645904 tested hGH 176-191 and five nearby fragments in normal rats (checked 24 Aug 2026). The fragment made blood sugar rise for a short time. Insulin stayed high for longer.
Other fragments with the 178-191 tail also made rats less sensitive to insulin. The paper reports no human result. PubMed lists no grant.
What did the 2022 cell study find?
PMID 35783198 put hGH Fragment 176-191 and doxorubicin in chitosan particles (checked 24 Aug 2026). Particles with both agents slowed MCF-7 breast-cancer cell growth more than particles with doxorubicin alone.
This was computer and cell work. It did not test weight loss or give the fragment to a person.
Jazan University funded the work through grant JUP8/318. The authors reported no conflicts.
What does an original user report say?
An original r/steroids thread appeared on 2 July 2019 (whole thread; checked 24 Aug 2026). The account is self-reported and self-selected. It names no sponsor.
“Lost 7lbs in 3 weeks ... how much of that was fat and how much was water/glycogen stores dropping from coming off cycle I have no idea, you be the judge.”
“I think the biggest contributing factor to the weight loss was me dropping back down to TRT ... the weight continued to drop off even when I would up calories.”
The author names diet, training, a recent cycle, TRT, water, and glycogen as other factors. The report proves self-use by July 2019. It does not prove what caused the weight change.
What does evidence tier C mean here?
Rat and cell studies exist for this fragment. No human clinical trial was found. Tier C stays right (checked 24 Aug 2026).
AOD-9604 human trials do not raise this fragment's tier.
What is the recorded EU status?
The EU Commission index has neither exact name (Union Register index; checked 24 Aug 2026). The searches used hGH Fragment 176-191 and somatotropin (176-191). The EU field stays unclear.
What does this register entry cover?
This entry covers native hGH Fragment 176-191. It does not cover AOD-9604.
→ AOD-9604 register entry → What can be in a vial → All register entries